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Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults 
for which there is currently no treatment. The pathogenesis of this autosomal dominant 
disorder is associated with the expansion of CTG repeats in the 3′-UTR of the DMPK 
gene. DMPK transcripts with expanded CUG repeats (CUGexpDMPK) are retained in the 
nucleus forming multiple discrete foci, and their presence triggers a cascade of toxic 
events. Thus far, most research emphasis has been on interactions of CUGexpDMPK with 
the muscleblind-like (MBNL) family of splicing factors. These proteins are sequestered 
by the expanded CUG repeats of DMPK RNA leading to their functional depletion. As a 
consequence, abnormalities in many pathways of RNA metabolism, including alternative 
splicing, are detected in DM1. To date, in vitro and in vivo efforts to develop therapeutic 
strategies for DM1 have mostly been focused on targeting CUGexpDMPK via reducing 
their expression and/or preventing interactions with MBNL1. Antisense oligonucleotides 
targeted to the CUG repeats in the DMPK transcripts are of particular interest due to 
their potential capacity to discriminate between mutant and normal transcripts. However, 
a growing number of reports describe alternative strategies using small molecule chem-
icals acting independently of a direct interaction with CUGexpDMPK. In this review, we 
summarize current knowledge about these chemicals and we describe the beneficial 
effects they caused in different DM1 experimental models. We also present potential 
mechanisms of action of these compounds and pathways they affect which could be 
considered for future therapeutic interventions in DM1.
Keywords: myotonic dystrophy type 1, myotonic dystrophy type 1 pathogenesis, sequestration of muscleblind-
like 1, antisense oligonucleotides, aberrant alternative splicing, small molecule compounds
iNTRODUCTiON
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults leading to 
disability and shortened lifespan (1). There is currently no treatment for DM1. The symptoms of this 
disease include myotonia, muscle weakness and wasting, cardiac conduction defects, diabetes and 
insulin resistance, and cataracts. DM1 belongs to a larger group of microsatellite disorders associated 
with expansions of simple repetitive elements within specific genes (2). This autosomal dominant 
disease is caused by the expansion of CTG repeats in the 3′-UTR of the DMPK gene and its pathogen-
esis is mediated, at least in part, by a toxic RNA gain-of-function mechanism. Molecular hallmarks of 
DM1 cells expressing mutant DMPK transcripts (CUGexpDMPK) are nuclear RNA foci. Their pres-
ence has an adverse effect on host cells leading to a broad spectrum of abnormalities. Recent studies 
FigURe 1 | Small molecule compounds alleviating myotonic dystrophy type 1 
(DM1) pathogenesis. Small molecule compounds which mitigated DM1 
pathogenesis in different experimental systems are shown. The molecules are 
classified into a few categories depending on their presumable mechanisms 
of action. All the molecules are believed to act independently of direct 
interactions with expanded CUG repeats RNA.
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of the dynamics of CUG repeat foci have revealed that these are 
unstable, constantly aggregating, and disaggregating structures 
(3), and muscleblind-like (MBNL)1 protein is directly involved 
in the stochastic process of foci formation. Being associated with 
CUGexpDMPK, the MBNL1 protein has a role in stabilizing RNA 
aggregates and its downregulation resulted in the decrease of RNA 
foci accumulation (3). However, MBNL1 depletion does not com-
pletely eliminate CUG foci, which suggests involvement of other 
proteins in mutant transcripts retention. In fact, as demonstrated 
experimentally, proteins other than MBNL1 may be recruited to 
the CUG repeat inclusions. Such recruitment may involve limited 
colocalization, as shown for hnRNP H, hnRNP F, and DDX6 
proteins, or it may represent only close association with the RNA 
foci as shown for SC35 protein (4–7). In addition to the depletion 
of proteins in CUG RNA foci, DM1 pathogenesis also involves 
aberrant protein synthesis and/or their altered stability as shown 
for CUGBP1 protein (8, 9).
Muscleblind-like 1 and CUGBP1 are antagonistic regulators of 
splicing. MBNL1 is a zinc finger protein which recognizes both 
RNA sequence (YGCY) and structural elements (hairpins) con-
taining pyrimidine mismatches on either normal splicing sub-
strates or pathogenic mutant repeat RNA (10). As shown in vitro, 
the protein binds selectively to the stem region of expanded CUG 
RNA, and such interaction is detected in DM1 cells as MBNL1 
sequestration and colocalization with mutant CUG repeats 
(11, 12). On the other hand, CUGBP1 protein binds in vitro to 
single-stranded regions of GU-containing transcripts; however, 
the protein is not enriched in the RNA foci. In DM1 cells, CUGBP1 
becomes hyperphosphorylated, stabilized, and consequently, 
overexpressed (9). Changes in cellular levels and activities of 
MBNL1 and CUGBP1 proteins result in the abnormal expression 
of embryonic splice variants in adult tissues which is one of the 
molecular hallmarks of DM1 pathogenesis. Besides regulating 
splicing, both proteins are also involved in mRNA translation, 
RNA stability, protein secretion, and localization of alternative 
3′UTR isoforms (13, 14). Their altered activity in DM1 cells also 
correlate with changes in signaling pathways of various protein 
kinases including cyclin-dependent kinases (CDKs), glycogen 
synthase kinase 3β (GSK3β), AKT, and protein kinase C (PKC) 
(8, 15, 16).
In vitro and in vivo efforts to develop DM1 therapeutic strategies 
have been mostly aimed at destroying the toxic ribonucleoprotein 
complexes via targeting the mutant CUGexpRNA and/or inhibit-
ing its pathogenic interactions with MBNL1 protein, leading to 
the generation of several strategies that proved to have a beneficial 
effect in DM models (17, 18). Thus far, antisense technology 
that utilizes synthetic siRNAs (19), modified CAG antisense 
oligonucleotides (20–22), viral vector-mediated expression of 
hU7-snRNA-(CAG) (23), or a hammerhead RNA (ribozyme) 
(24) designed to cut CUG repeats, appear effective in DM1 cells 
and mouse models of the disease. Moreover, morpholino CAG 
oligonucleotides (25, 26) and several bioactive small molecules 
(27–34), which are CUG repeat binders, have been reported as 
potential therapeutic agents for DM1, capable of inhibiting the 
interactions between expanded CUG RNA and MBNL1 protein.
As our understanding of the pathogenesis of DM1 has grown 
over the past years, the focus of the research encompassed more 
molecular events being important for the progression of the 
disease, e.g., aberrantly spliced genes, RAN translation (35), and 
deregulation of miRNAs (36). Considering that DM1 is a multi-
system disorder, it seems reasonable to target multiple molecules 
and pathways of the misregulated DM1 apparatus with the aim of 
developing a beneficial strategy to combat DM1.
Over the past few years, experimental evidence has indicated 
that, indeed, small molecule chemicals affecting different cellular 
pathways independently of CUGexpDMPK can mitigate some of 
the molecular hallmarks of DM1 pathogenesis (18). However, 
it remains elusive, how the molecules alleviate DM1 features. 
Their efficiency, though, indicates that it is reasonable to search 
for novel candidate therapeutic targets that will provide new 
opportunities for future studies aiming to decipher the complex 
pathomechanism of DM1. In this review, we summarize current 
knowledge about such molecules, acting independently of direct 
binding to CUGexpDMPK, and we describe beneficial effects they 
caused in different DM1 experimental models. We also present 
potential mechanisms of action of these compounds and cellular 
pathways they affect which could be considered for future thera-
peutic interventions in DM1.
iNHiBiTORS OF TRANSCRiPTiON
A few compounds that inhibit transcription and alleviate some of 
the molecular symptoms of DM1 have been identified in recent 
years. These include pentamidine and its analogs, as well as 
actinomycin D (ActD) (Figure 1) (37–40).
Pentamidine
Pentamidine is an FDA-approved drug currently used to treat 
patients with Pneumocystis carinii infections (pneumonia) in acquired 
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immunodeficiency syndrome, as well as patients with Trypanosomiasis 
and Leishmaniasis infections (41, 42). Pentamidine is a diamide 
composed of two phenyl amidine groups joined by a five-carbon 
methylene linker (Table 1). It has been speculated to inhibit the 
splicing of essential group I introns in P. carinii, preventing its 
growth (43, 44), and it was recently shown to inhibit translation 
by binding tRNA (45). Pentamidine may also block DNA replica-
tion (41), since its structure with DNA showed binding in the 
minor groove of the double-stranded molecule (46). Therefore, it 
is likely to interact with many different nucleic acid targets within 
cells. Interestingly, in DM1 patient’s cells and model organisms’ 
pentamidine disrupted CUG RNA foci, released MBNL1 protein, 
and reversed aberrant alterative splicing of some pre-mRNAs 
typically misspliced in DM1. Initially, these effects were thought 
to be caused by binding of the compound to the CUG repeats, 
because of its ability to bind DNA (40), however, subsequently it 
was found that its effect on the DM1 molecular phenotype was 
attributed to either decreased transcription of the CUG transcripts 
or increased degradation of the toxic RNA (38). So far, the benefi-
cial effects of pentamidine have been shown in HeLa and HEK293 
cells transfected with 960 CUG repeats and in model organisms, 
including the HSALR mice and a Drosophila model expressing 
250 CTG repeats (37, 40) (Table S1 in Supplementary Material). 
Treatment of HeLa cells transiently expressing CUG repeats and 
transgenic HSALR mice showed, respectively, a decrease of CUG 
mRNA expression (and subsequent reduction of CUG RNA foci 
number), and a reduction of the HSA transcript. Correction of 
some misspliced pre-mRNAs, i.e., cTNT E5 and INSR E11 (in 
HeLa cells) and Clcn1 E7a and Serca1 E22 (in HSA mice) was 
attributed to the liberation of MBNL1 protein from diminished 
CUG foci and reduction of CUG transcript levels. This suggests 
that pentamidine does not directly block MBNL1 binding to the 
repeats and supports the hypothesis that it either inhibits tran-
scription of the CTG repeats or increases the rate of CUGexpRNA 
degradation. However, in a DM1 Drosophila model, a behavioral 
and molecular improvement which included a minor rescue of 
cardiac defects reduced CUG foci, and Mbnl1 displacement was 
not correlated with diminished expression level of CUG repeats 
mRNA (37) (Table S1 in Supplementary Material). It was sug-
gested that the beneficial effects induced by pentamidine are due 
to Mbnl1 diffusion and subsequent dispersion of toxic RNA in 
the nucleus, rather than by inhibition of transcription of the toxic 
RNA or its degradation.
Pentamidine Analogs
The results obtained with pentamidine as an anti-DM1 drug were 
promising; however, they showed a certain degree of toxicity and 
thus needed optimization, and the mechanism of action (MoA) 
needed clarification. To improve the physiochemical properties 
of pentamidine and to decrease its toxicity, a series of analogs 
of pentamidine, containing between three to nine methylene 
carbons, were analyzed for their ability to rescue splicing of tran-
siently transfected minigenes in a HeLa cell model of DM1 and in 
HSALR mouse model (Table S1 in Supplementary Material). Two 
different minigenes, i.e., cTNT E5 and INSR E11, containing exons 
that are misspliced in DM1 were tested. Propamidine (methylene 
linker length of 3) and heptamidine (methylene linker length of 7) 
(Table 1) were identified as the most promising analogs in res-
cuing missplicing in both DM1 models (38). Although analogs 
with more methylenes rescued missplicing more efficiently, an 
increase of the methylene linker length also reduced solubility 
and increased toxicity. Interestingly, in the HeLa cell model only 
propamidine was able to reduce CUG repeat transcript levels in 
a dose-dependent manner (however, not as effectively as penta-
midine), whereas no reduction was observed with heptamidine 
treatment before significant cell death occurred. The cTNT splic-
ing was improved to varying degrees with different linker analogs, 
however, no correction was observed with propamidine at con-
centrations which were not toxic. Furthermore, the improvement 
was not dependent on inhibition of CUG transcript expression. 
Unlike the cTNT, all linker analogs partially or fully rescued the 
missplicing of INSR E11 after CUG repeats expression. Different 
MBNL targets may require different concentrations of the proteins 
to be properly regulated, which could explain the results found 
regarding correction of alternative splicing of different genes (47).
Treatment of HSALR DM1 mice with heptamidine caused 
reduction of both the mRNA and pre-mRNA levels of the 
transgene, while in HSASR mice expressing short CTG repeats, 
no such reduction was detected. This suggests that the effect was 
dependent on the presence of extended repeats, rather than the 
HSA promoter, transgene, or the short repeats. In the HSALR 
mouse model, heptamidine completely reversed the missplicing 
of Clcn1 E7a, while splicing of Atp2a1 E22 was rescued partially 
and at lower concentrations than pentamidine. In addition, hep-
tamidine caused a rapid (after 1 week) and significant reduction 
of myotonia, as well as diminished levels of HSALR transcript 
(Table S1 in Supplementary Material). Nevertheless, it showed 
high toxicity in the mouse model. However, variation of the linker 
length of pentamidine resulted in significant improvements and 
is encouraging to develop a therapy for DM1. Reduction of the 
CUG transcript in in  vitro transcription assays as well as in 
both DM1 models, i.e., HeLa cells and HSALR mice, as well as 
reduced formation of nuclear foci, suggest that pentamidine and 
its analogs most likely inhibit transcription of CTG*CAG repeat 
DNA. However, other possible mechanisms cannot be ruled 
out as pentamidine is a DNA-binding molecule and may affect 
expression of other genes, some of which may be regulators of 
alternative splicing.
Further modifications of pentamidine and heptamidine to 
modify their size, solubility, degrees of freedom, number of hydro-
gen bond donors, and hydrophobicity led to the generation of 
new promising compounds. These molecules were tested for their 
ability to correct splicing defects in cellular and transgenic mouse 
models of DM1, as well as their toxicity relative to the parental 
compounds (48). Three different series of molecules varying in 
amidine substitution, central linker length, and planarity were 
synthesized. Compound 8, a molecule with an un-substituted 
propyl chain, was able to rescue missplicing in the DM1 HeLa 
cell model with no toxicity at the range of concentrations used, 
but it was half as effective as pentamidine. Modification of the 
planarity produced a linear molecule, compound 12, and a 
molecule with a concave shape, compound 13 (Table  1). Both 
compounds rescued missplicing similarly to pentamidine and 
they were not toxic over the range of concentrations needed for 
TABle 1 | Molecular formula and chemical structure of small molecule compounds which do not directly target expanded CUG repeats and alleviate pathogenesis of 
myotonic dystrophy type 1.
Name Molecular formula Structure Potential mechanism of action
Pentamidine C19H24N4O2 Inhibition of transcription
Propamidine C17H20N4O2
Heptamidine C21H28N4O2
Compound 13 C18H16N4O
Actinomycin D C62H86N12O16
Phenylbuthazone C19H20N2O2 Upregultion of muscleblind-like 1
(Continued)
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Name Molecular formula Structure Potential mechanism of action
Ketoprofen C16H14O3
ISOX C22H30N4O6
Vorinostat C14H20N2O3
Manumycin A C31H38N2O7 Inhibition of H-RAS pathway
Metformin C4H11N5 Modulation of protein kinases
AICAR C9H14N4O5
Ro 31-8220 C25H23N5O2S
C16 C13H8N4OS
TABle 1 | Continued
(Continued)
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Name Molecular formula Structure Potential mechanism of action
C51 C23H21N5
Lithium chloride LiCl
TDZD-8 C10H10N2O2S
6-Bromoindirubin-3′-oxime C16H10BrN3O2
Harmine C13H12N2O Undetermined
TABle 1 | Continued
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the rescue, unlike pentamidine. Compound 12 affected splicing 
in a DM-independent manner in a model without CUG expan-
ded repeats, suggesting a modulation of splicing through a 
mechanism beyond targeting the CUG repeats. On the contrary, 
compound 13 only rescued alternative splicing in the presence of 
CUG repeats. Furthermore, it reduced foci in the DM1 HeLa cell 
model and partially rescued misplicing of Clcn1 E7a and Atp2a1 
E22 in the HSALR mouse model at a similar level observed with 
heptamidine, but without the associated toxicity (39).
The MoA of pentamidine has been previously proposed to be 
inhibition of transcription through binding to the CTG repeats 
or reduction of the stability of the transcript. Nonetheless, bind-
ing to the CUG repeats and therefore displacement of MBNL1 
proteins, especially in the case of the analogs generated has not 
been completely ruled out, and further work is required to clarify 
the MoA of the diamines as anti-DM1 drugs.
Actinomycin D
Actinomycin D (Table 1) is a polypeptide antibiotic which forms 
a stable complex with double-stranded DNA, inhibiting DNA-
primed RNA synthesis and causing single-stranded breaks in 
DNA, therefore stopping the proliferation of cells (49, 50). ActD 
is an FDA-approved anti-cancer drug with activity to inhibit 
global transcription. More recently, this antibiotic was shown 
to improve the DM1 molecular phenotype (39). ActD does not 
bind to CUG repeat RNA in vitro, however, low concentrations, 
insufficient to affect global transcription, triggered a significant 
reduction of expression of the expanded CUG repeat RNA in 
HeLa cells and in DM1 fibroblasts, by 50–70% and by 44–60%, 
respectively. At effective dosages, ActD was mildly toxic to HeLa 
cells causing reduction of nuclear CUGexpRNA foci by 50% and 
releasing MBNL1 from the foci. In HSALR mice, the molecule 
specifically reduced mRNA levels of the repeat-containing HSA 
transgene and completely rescued the aberrant splicing of Clcn1 
E7a, whereas partially corrected splicing of a few other genes, 
i.e., Atp2a1 E22, Mbnl1 E7, Vps39 E3, Nfix E7, and Ldb3 E11. 
Importantly, at the range of dose used these changes were not 
correlated with global inhibition of transcription (Table S1 in 
Supplementary Material). The MoA of ActD in DM1 is yet to be 
determined. However, its effects produced in the disease models 
suggest inhibition of transcription of the CUGexpRNA by binding 
to the CTG repeats in DNA and blocking the RNA polymerase. 
Such mechanism is feasible since it is known that ActD interca-
lates into GC-rich sequences, stabilizing topoisomerase-I DNA 
complexes and preventing RNA polymerase progression (51).
COMPOUNDS UPRegUlATiNg MBNl1
Overexpression of MBNL1 protein has been shown to alleviate 
pathogenesis of DM1 by reversal of aberrant alternative splicing 
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and rescue of myotonia (52). Accordingly, small molecules 
which upregulate expression of the splicing factor would have 
a potential of becoming therapeutic molecules for DM1. Two 
compounds with such capacity have been identified by Chen 
et  al. (53). Phenylbutazone (PBZ) and ketoprofen (Table  1) 
belong to nonsteroidal anti-inflammatory drugs (NSAIDs) 
which are used to reduce pain and fever, prevent blood clots, 
and in higher doses, decrease inflammation. NSAIDs inhibit the 
activity of cyclooxygenase enzymes (COX-1 and/or COX-2). 
These enzymes participate in the synthesis of key biological 
mediators in the cells, such as prostaglandins which are involved 
in inflammation, and thromboxanes which are involved in blood 
clotting (54, 55).
It was shown that PBZ enhances MBNL1 expression in pro-
liferating and differentiating C2C12 cells in a dose-dependent 
manner (53) (Table S1 in Supplementary Material). Consistent 
with this result, when analyzed in HSALR DM1 mice PBZ elevated 
the expression of Mbnl1 mRNA and protein in tibialis anterior 
and in quadriceps muscles. Interestingly, the expression of 
CUGBP1 remained unchanged after the treatment with PBZ. 
Consequently, the treated mice showed partial rescue of aberrant 
splicing of MBNL1-dependent exons, such as Clcn1 E7a, Nfix 
E7, and Rpn2 E17, whereas no splicing correction was found 
for CUGBP1-regulated exons. Amelioration of the molecular 
features in HSALR mice was further confirmed in behavioral and 
histological tests and the mice had an increase of grip strength 
and decrease in the number of muscle fibers with central nuclei 
(53). Although PBZ elevated Mbnl1 expression levels in HSA 
mouse muscles, colocalization of the protein with CUG RNA foci 
was markedly attenuated by its treatment. This result suggests that 
PBZ inhibits the interaction between CUG RNA foci and MBNL1 
and reduces the ratio of MBNL1 in the mutant transcript. The 
precise MoA of PBZ in DM1 remains unclear and it is speculated 
that it may not be limited to the liberation of MBNL1 proteins 
from CUGexpRNA. The observed upregulation of MBNL1 mRNA 
was attributed to demethylation of its intron 1, making this region 
to act as an enhancer of transcription (53).
Ketoprofen is another NSAID which was able to upregulate 
MBNL1 levels in C2C12 cells (53). In a Drosophila model of 
DM1 expressing 480 interrupted CUG repeats the compound 
suppressed CUG-mediated lethality (56). The MoA of ketoprofen 
in DM1 has not yet been elucidated.
More recently, a flow cytometry-based screen led to identifica-
tion of small compounds that upregulated MBNL1 and partially 
rescued splicing defects in DM1 patient-derived fibroblasts (57). 
Using engineered HeLa cells containing a ZsGreen fluorescent tag 
in the N-terminus of the MBNL1 sequence, the HDAC inhibitors 
ISOX, and Vorinostat (Table 1) were found to produce a 2- and 
1.8-fold increase of the ZsGreen-MBNL1 signal, respectively 
(57). Treatment of either normal or DM1 fibroblasts with ISOX 
and Vorinostat produced a significant increase of MBNL1 levels, 
and partially rescued the splicing of SERCA1 e22 and INSR e11 in 
both cell lines (Table S1 in Supplementary Material). Since ISOX 
and Vorinostat are HDAC inhibitors, they may affect expression 
of SERCA1, INSR, and DMPK mRNAs. However, as shown by 
Zhang and coauthors, treatment of normal and DM1 fibroblasts 
with these molecules caused no significant changes in the genes 
levels. The MoA of ISOX and Vorinostat is not fully clear, but 
inhibition of HDAC appears to have a role in modulating MBNL1 
levels, and the effects might be caused by inhibition of several 
HDACs. ISOX inhibits HDAC6 at low concentrations, but also 
inhibits HDAC1 and other HDACs at higher concentrations. 
Vorinostat is an FDA-approved HDAC inhibitor for the treatment 
of cutaneous T cell lymphoma, and inhibits class I and class II 
HDACs, altering gene transcription and causing cell cycle arrest. 
Nonetheless, in the light of these recent results, modulation of 
MBNL1 through mechanisms other than inhibition of HDAC 
cannot be completely ruled out (57).
iNHiBiTORS OF H-RAS PATHwAY
The Ras family includes three members: H-Ras, K-Ras, and 
N-Ras. They play roles in a large number of biological processes 
including cell morphology, survival, apoptosis, gene expression, 
and alternative splicing regulation (58). Posttranslational modi-
fications of Ras proteins lead to their activation and these modi-
fications include farnesylation of H-Ras, as well as farnesylation 
and geranylgeranylation of K-Ras and N-Ras (59). Manumycin A 
(Table 1) is an FDA-approved antibiotic that acts as a potent and 
selective farnesyltransferase (FTase) inhibitor (60). By inhibiting 
FTase, manumycin A prevents activation of H-Ras protein but 
has no effect on K-Ras and N-Ras. It has been reported that some 
of DM1 features can be alleviated by exposure to manumycin A 
(Figure 2) (61). Treatment of HSALR DM1 mice with the com-
pound led to correction of Clcn1 E7a splicing, what was linked 
to the inhibition of H-Ras activity since siRNA knockdown of 
endogenous H-Ras protein recapitulated improvement of the 
splicing. Such effect was not detected when the two other Ras 
proteins were downregulated. Although skeletal muscle injec-
tions with manumycin A corrected aberrant splicing of Clcn1 in 
DM1 mice, splicing of two other genes, Serca1 E22 and m-Titin 
Mex5, was not altered (61). Importantly, in this experimental 
model of DM1, manumycin A did not alter expression of Mbnl1 
and Cugbp1, which are involved in splicing regulation of Clcn1 
E7a, Serca1 E22, and m-Titin Mex5 (Table S1 in Supplementary 
Material). Thus, it was concluded that the effect of manumycin 
A on aberrant splicing was independent of these two splicing 
factors. Therefore, it is possible that manumycin A, which acts 
as a Ras FTase inhibitor, triggers alterations in H-Ras signaling. 
This may influence a trans-acting factor(s) other than MBNL1 
and CUGBP1 involved in alternative splicing and may contribute 
to chloride channel splicing. However, a category of trans-acting 
factor(s) affected remains unknown.
MODUlATORS OF PROTeiN KiNASeS
Protein Kinase inhibitors
Pathogenesis of DM1 has been linked to disrupted protein kinase 
signaling pathways. Altered expression and nonspecific activation 
have been shown for PKC, Src family kinases, CDKs, GSK3β, and 
protein kinase AKT (8, 15, 16). Current studies in DM1 with the 
use of small molecule inhibitors of protein kinases have shed light 
on a potential alternative strategy in DM1 therapeutic interven-
tion. Screening of several libraries of small molecule compounds, 
FigURe 2 | Therapeutic effects of small molecules on myotonic dystrophy type 1 (DM1) pathogenesis. DM1 is characterized by the presence of RNA foci which are 
aggregations of the mutant CUGexp transcript with muscleblind-like (MBNL)1 and other proteins. CUGBP1 is not sequestered by foci, but it is upregulated. The 
imbalance of these two alternative splicing proteins causes the aberrant alternative splicing of many pre-mRNAs. Treatment of DM1 cells and model organisms with 
small molecules that target the DNA and/or affect proteins involved in the DM1 pathogenesis can lead to beneficial effects, such as inhibition of transcription of the 
mutant transcript, or its degradation, release of MBNL1 protein from RNA foci, downregulation of CUGBP1 protein, and ultimately the correction of the aberrant 
splicing.
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including phosphatase and kinase inhibitors, using a medium 
throughput phenotypic assay by Ketley et al. led to the identifica-
tion of such molecules (62). Based on the identification of nuclear 
foci in DM1 cells using in  situ hybridization and high-content 
imaging, Ro 31-8220 (Table  1) was identified as a compound 
of potential therapeutic benefit in DM1. The compound elimi-
nated nuclear CUGexpRNA foci, reduced MBNL1 protein in the 
nucleus, affected SERCA1 E22 alternative splicing, and decreased 
steady-state levels of CUGBP1 protein (Figure  2). Ro 31-8220 
was previously identified as a PKC inhibitor and seen to affect the 
hyperphosphorylation of CUGBP1 and ameliorate the cardiac 
phenotype in a DM1 mouse model (8, 63). Nonetheless, Ketley 
et al. demonstrated that Ro 31-8220 acts independently of PKC 
on DM1 pathomechanism, suggesting the involvement of other 
kinases. Although the MoA of Ro-31-8220 still requires further 
investigation, the compound is likely to work independently of 
CUG repeat RNA binding.
Another study has identified two compounds, C16, an 
imidazolo-oxindole inhibitor and C51, a pyrimidine-based 
inhibitor (Table 1), of kinase inhibitory activity with the potential 
to alleviate DM1 molecular phenotype (64). Previous studies 
have described these two compounds as ATP-site directed PKR 
inhibitors (30, 65); however, activity of C16 against kinases other 
than PKR has also been reported (66). C16 has been successfully 
used in vitro and in vivo as an effective and versatile neuroprotec-
tive agent and shown to have potential value in the treatment of 
neurodegenerative diseases (66–69). Results by Wojciechowska 
et al. demonstrate that C16 and C51 may have therapeutic poten-
tial in patients with DM1 as well. These compounds produced a 
redistribution of the MBNL1 protein sequestered in CUGexpRNA 
foci and a reduction of the steady-state levels of CUGBP1. These 
actions were accompanied by correction of the aberrant alterna-
tive splicing of MBNL1-dependent (SERCA1 E22, DMD E78, 
MBNL1 E7, and LDB3 E7) and CUGBP1-dependent (ITGA6 
E24, MTMR3 E16, and SORBS1 E6) pre-mRNA targets, shifting 
the patterns of spicing toward those observed in non-DM cells. 
However, despite causing the nuclear CUGexpRNA foci to become 
less abundant, as determined by in situ RNA hybridization and 
immunocytochemistry for MBNL1 protein, the compounds did 
not eliminate foci completely.
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gSK3β inhibitors
Glycogen synthase kinase 3β has been seen to have a role in DM1 
pathogenesis (16). This kinase phosphorylates cyclin D3 at T283, 
which triggers degradation of the cyclin. Cyclin D3 associates 
with CDK4 and the resulting complex phosphorylates CUGBP1 
at S302 and regulates the translational activity of the protein. 
CUGBP1 regulates translation of proteins important for skeletal 
muscle development, thus its normal translational activity is 
required for a proper myogenesis. In muscle biopsies of DM1 
patients, GSK3β was found to be increased, causing a degrada-
tion of cyclin D3 and a reduced phosphorylation of CUGBP1 at 
S302, what was linked to delayed myogenesis. The presence of 
CUG expanded repeats appears to increase the stability of GSK3β 
by causing the autophosphorylation of the protein at Y216 (16, 
70). Altogether, these observations point at GSK3β as a potential 
therapeutic target in DM1. Indeed, treatment of HSALR mice with 
two GSK3β inhibitors, lithium and TDZD-8 (thiadiazolidine) 
(Table 1), reduced the levels of GSK3β in skeletal muscle and nor-
malized the levels of cyclin D3, restoring CUGBP1 translational 
function. These changes improved skeletal muscle strength in the 
mice and reduced myotonia, suggesting that correction of GSK3β 
may have a beneficial effect on myofiber regeneration (16).
Another GSK3β inhibitor, 6-bromoindirubin-3′-oxime (BIO) 
(Table 1), was used to treat young HSALR mice, resulting in recov-
ery of the grip strength to near-normal levels and the effect was 
maintained for several months after completion of the treatment. 
In addition, the levels of GSK3β and cyclin D3 in 12-month-old 
mice previously treated with BIO were similar to those in control 
mice, and the translational activity of CUGBP1 was corrected. 
Results from this study suggest that inhibition of GSK3β in young 
mice is sufficient to maintain corrected levels of the GSK3β-cyclin 
D3-CUGBP1 pathway and nearly normal muscle health over a 
long period of time after completion of the treatment (71).
Activators of AMP-Activated Protein 
Kinase (AMPK)
Metformin (Table  1) is an FDA-approved antidiabetic drug 
and was earlier reported to improve hyperglycemia through 
increased insulin-independent glucose uptake in peripheral 
muscles of DM1 patients (72). Most recently, metformin was 
investigated in in vitro DM1 models of human embryonic stem 
cells and in primary myoblasts derived from patients (73). The 
drug appeared to modify the alternative splicing of a subset of 
genes associated with DM1 in these cell models, as it partially 
rescued the aberrant splicing of INSR E11, CLCN1 E7a, TNNT2 
E5, ATP2A1 E22, and DMD E78. The effect on the modification 
of the alternative splicing has been linked to the inhibition of the 
complex I of the respiratory chain, which in turn raises the intra-
cellular AMP/ATP ratio, which triggers the activation of AMPK. 
The role of AMPK activation in alternative RNA splicing was 
tested in DM1 myogenic progenitor cells and in myoblasts with 
the AMPK activator AICAR [5-aminoimidazole-4-carboxamide 
1-β-d-ribofuranoside, Acadesine, N1-(β-d-ribofuranosyl)-5-
aminoimidazole-4-carboxamide] (73). Treatment of DM1 cells 
promoted changes in similar subsets of pre-mRNAs as found for 
metformin. However, AICAR did not modulate the INSR E11 
splicing in the cells used. Thus, these results suggest that activation 
of AMPK is partially involved in alternative splicing modulation, 
but metformin appears to trigger an additional molecular path-
way. Interestingly, metformin decreases tyrosine kinase recep-
tor signaling (73). The tyrosine kinase receptors include the 
epidermal growth factor receptor, the signaling pathway which 
controls INSR E11 inclusion via the inhibition of hnRNPA1 and 
hnRNPA2B1 expression (74, 75). This could explain the effect of 
metformin on the alternative splicing of INSR. The MoA behind 
other splicing events modulated by metformin but not by AMPK 
activation remains unclear.
SMAll MOleCUleS OF NATURAl 
ORigiN
Many small molecules have been synthesized as potential 
therapies for DM. However, only a few studies have reported 
utilization of molecules of natural origin (40, 76). Recently, a set 
of plant-derived alkaloids was identified as small molecules with 
an anti-DM1 effect (77). Using a novel CUG78–MBNL1 complex 
inhibition assay, a collection of isolated natural compounds 
and extracts from plants and fungal strains was screened. The 
bioactivity of the compounds was investigated in human DM1 
cells and HSALR mice resulting in the identification of several 
alkaloids, including carboline harmine and isoquinoline berber-
ine, which ameliorated certain aspects of the DM1 pathology in 
these models.
Aromatic alkaloids can interact with RNA, and indeed ber-
berine and harmine (Table 1) have been reported to bind RNA 
structures (78, 79). In DM1 myoblasts, harmine reduced foci, 
nevertheless it did not improve the histology in gastrocnemius 
muscle of the HSALR mice, as the percentage of fibers with inter-
nalized nuclei was not altered by the treatment of the mice with the 
compound (77). However, although harmine increased the levels 
of MBNL1 in DM1 myoblasts and enhanced MBNL1-dependent 
alternative splicing of cTNT E5, INSR E11, and Clcn1 E7a (Table 
S1 in Supplementary Material), a similar effect was found in wild-
type myoblasts, suggesting that inhibition of the CUG–MBNL1 
complex is not the primary MoA of this alkaloid. Consequently, 
it was suggested that harmine acts through another mechanism 
that causes the increase of MBNL1 levels and the amelioration of 
the spliceopathy. Despite the side effects, harmine represents an 
interesting small molecule that could be optimized by chemical 
modifications to become a potential DM1 therapy.
CONClUSiON
Myotonic dystrophy type 1 is a life-shortening, debilitating dis-
order for which there is currently no treatment. Pathogenesis is 
associated with nuclear retention of mutant DMPK mRNA which 
attract or is attracted by various proteins. Experimental data sug-
gest that the formation of riboprotein complexes is a necessary 
trigger for DM1 pathogenesis. Thus, compounds which reduce 
such inclusions would be therapeutically beneficial. Over the past 
few years, many efforts have been focused on the synthesis of 
small molecule chemicals specifically recognizing mutated CUG 
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